◀ Back to MTOR
BCL2 — MTOR
Text-mined interactions from Literome
Asnaghi et al., Oncogene 2004
:
Bcl-2 phosphorylation and apoptosis activated by damaged microtubules
require mTOR and are regulated by Akt
Tirado et al., Oncogene 2005
:
Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of
Bcl-xL was
caused by the
mTOR inhibitory action of rapamycin, which prevented cap dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity
Kasper et al., Curr Opin Oncol 2007
(Sarcoma) :
Included are recent developments in targeted therapy, focusing on the following : antiangiogenic and immunomodulatory drugs ( e.g. anti-cytotoxic T lymphocyte associated antigen-4 monoclonal antibody ),
Bcl-2 antisense therapy, raf kinase and
mammalian target of rapamycin inhibition , heat shock protein modulators, minor groove binders and other agents being developed
Kasper et al., Rev Recent Clin Trials 2007
(Sarcoma) :
Moreover, we give an overview on the emerging compounds for patients with soft tissue sarcoma including recent developments of targeted therapy focusing on antiangiogenic and immunomodulatory drugs,
Bcl-2 antisense therapy, raf kinase and
mTOR inhibition , minor groove binders, and other agents being developed
Ramanathan et al., Proc Natl Acad Sci U S A 2009
:
Bcl-xl, but not VDAC1, is a kinase substrate for mTOR in vitro, and
mTOR regulates the association of
Bcl-xl with mTOR
Guo et al., Zhonghua Xue Ye Xue Za Zhi 2012
(Precursor Cell Lymphoblastic Leukemia-Lymphoma) :
Oridonin inhibited activation of ABL kinase and its downstream
Akt/mTOR , Raf/MEK/ERK and STAT5 signaling pathways, which were constitutively activated in SUP-B15 cell line,
down-regulated the level of anti- apoptotic protein
Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax
Rahmani et al., Cancer Res 2013
(Leukemia, Myeloid) :
PI3K/mTOR inhibitors markedly downregulated Mcl-1 but
increased Bim binding to
Bcl-2/Bcl-xL ; the latter effect was abrogated by ABT-737 ...
PI3K/mTOR inhibitors markedly downregulated Mcl-1 but
increased Bim binding to
Bcl-2/Bcl-xL ; the latter effect was abrogated by ABT-737